Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease.

"Conflicts of interest These authors disclose the following: Gil Y. Melmed has consulted for AbbVie, Boehringer-Ingelheim, Janssen, Pfizer, Samsung Bioepis, and Takeda, and has received research funding from Pfizer for an unrelated investigator-initiated study. Jonathan Braun has received research funding from Janssen. John Prostko, James L. Stewart, and Edwin C. Frias work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study. Dermot P. B. McGovern: Pfizer and Takeda. Michael Chiorean: Abbvie, Janssen, Pfizer, and Takeda. Erica Cohen: Abbvie and Pfizer. David Fudman: Pfizer. Caroline Hwang: Abbvie, Janssen, and Pfizer. Donald Lum: Abbvie, Janssen, and Takeda. Ryan McConnell: Abbvie and Pfizer. Nimisha Parekh: Pfizer. Douglas Wolf: Abbvie, Janssen, Pfizer, and Takeda. Bradley Morganstern: Abbvie, Janssen, Pfizer, and Takeda. Sarah Glover: Abbvie, Janssen, and Takeda. Christina Ha: Abbvie, Janssen, and Pfizer. Gaurav Syal: research funding for unrelated investigator study from Pfizer. Corey Siegel: Abbvie, Jannsen, and Pfizer. Adam Ehrlich: Pfizer. Kimia Sobhani: Abbott Diagnostics. The remaining authors disclose no conflicts."

"Funding This study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported in part by the Cedars-Sinai Precision Health Initiative and the Erika J. Glazer Family Foundation."